ストックスクリーナーアプリを入手
222.82
1.35%
-3.06
アフターアワーズ：
223.20
0.38
+0.17%
Biogen Inc (BIIB) 最新ニュース
How At Home Alzheimer’s Treatment Could Impact Biogen (BIIB) Investors - Simply Wall Street
How Biogen Inc. (BIIB) Affects Rotational Strategy Timing - Stock Traders Daily
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs? - Zacks Investment Research
Biogen stock closes 0.55 percent higher as Q2 growth holds - AD HOC NEWS
Biogen (BIIB) Could Be 4% Undervalued After Strong Earnings And Product News - simplywall.st
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack - Yahoo Finance
Biogen stock slips before the bell after September 24 close - AD HOC NEWS
Biogen stock trades near its 52-week high on growth bets - AD HOC NEWS
Biogen stock adds 3.40 percent ahead of the open - AD HOC NEWS
Biogen Inc. (BIIB) Options ChainYahoo Finance - Yahoo! Finance Canada
Biogen Inc. stock reaches a new 52-week high - AD HOC NEWS
Biogen stock heads into the open after a 2.7 percent gain - AD HOC NEWS
Biogen stock hits 52-week high at 225.88 USD By Investing.com - Investing.com Australia
Biogen stock hits 52-week high at 225.88 USD - Investing.com
Biogen stock slips after a lower close and analyst notes - AD HOC NEWS
Biogen stock heads into the open after a 1.6 percent decline - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Learn Why The Bull Case For Biogen Stock Could Change Following At Home LEQEMBI Approval - simplywall.st
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day - Zacks Investment Research
Biogen Inc. stock holds near top of 52-week range after EMPAVELI data update - AD HOC NEWS
Biogen stock heads into the open after a 1.6 percent slide - ad-hoc-news.de
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size, Share & Growth Report, 2035 - SNS Insider
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Biogen Inc. stock reacts to Leqembi Pen approval and fresh guidance - AD HOC NEWS
Biogen acquires RayThera Inc. (August 2026) - app.dealroom.co
Biogen Inc. stock gains regulatory boost from Japan approval for Leqembi Pen - AD HOC NEWS
Biogen Inc. stock gains after new EMPAVELI kidney data publication - AD HOC NEWS
Biogen Inc. stock trades near 52-week high as analysts keep a Moderate Buy stance - AD HOC NEWS
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN - Biogen
Biogen: Growth Is Back, But It Came At A Price (NASDAQ:BIIB) - Seeking Alpha
Biogen Announces Published VALIANT Data Showing EMPAVELI Reduced Proteinuria in Adolescents with C3G and Primary IC-MPGN - Quiver Quantitative
Is Biogen Stock Outperforming the S&P 500? - finance.yahoo.com
Eisai and Biogen Announce Japan Approval of LEQEMBI Pen, a Once-Weekly Subcutaneous Alzheimer’s Treatment - Quiver Quantitative
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease - Yahoo Finance
Biogen (BIIB) Wins China Approval For At Home Weekly Alzheimer’s Treatment - simplywall.st
Biogen to Report Third Quarter 2026 Financial Results October 28, 2026 - Biogen
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside? - Yahoo Finance
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience - Yahoo Finance
Biogen Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.23% Potential Upside with Strategic Collaborations - DirectorsTalk Interviews
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - TradingView
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biogen stock heads into the open without fresh price data - ad-hoc-news.de
1.40%
大文字化:
|
ボリューム (24 時間):